Diploma Course on Research & Development of Products to Meet Public Health Needs
|
|
|
- Carmella Watson
- 7 years ago
- Views:
Transcription
1 Diploma Course on Research & Development of Products to Meet Public Health Needs Organized by Nagasaki University, Japan and Faculty of Allied Health Sciences, Thammasat University, in cooperation with Graduate School of Pharmaceutical Science, The University of Tokyo, Japan, Chulalongkorn University,, China Second Military Medical University, China, Universidad de Antioquia, Colombia 28 October 9 November, 2013 Objective: To provide basic knowledge and skills of the different steps in the whole process of PRD to research scientists, post-graduate students, medical doctors involved in PRD, regulatory authorities, professionals. Output: At the end of the course, the participants will be able to: 1. Describe the development activities related in the PRD process. 2.Integrate the various components needed for PRD and 3. Disseminate the knowledge to other scientists and institutions working in any aspect of PRD in order to work together Outcome: Increase research activity on PRD in DEC (Disease Endemic Countries) institutions Participants: Research scientists, post-graduate students, medical doctors involved in PRD, regulatory authorities, professionals. Research scientists/professionals: (1) Diploma degree in science (2) Involved as a member of the team in any aspect of PRD (3) Good track record- work ethics and ability to work as a team/recommendation letter from supervisor (4) Conversant in English Post-graduate students: (1) Accepted in the post-graduate program (2) Good track record- work ethics and ability to work as a team/recommendation letter from supervisor (3) Conversant in English
2 Medical doctors: (1) Degree in medicine (2) Involved as a member of the team in any aspect of PRD (3) Good track record- work ethics and ability to work as a team/recommendation letter from supervisor (4) Conversant in English Regulatory authorities: (1) Diploma degree (2) Member of the regulatory in the country (3) Good track record- work ethics and ability to work as a team/recommendation letter from supervisor (4) Conversant in English Course Language: English Course format: This is 12 days course consisting of lectures, open discussions, group activity, site visit and practical exercises on specific activities. Course Directors : Professor Dr. Juntra Laothavorn Institute of Tropical Medicine (NEKKEN) Nagasaki University, Nagasaki, Japan karbwangj@nagasaki-u.ac.jp Tel: Professor Dr. Kenji Hirayama Institute of Tropical Medicine (NEKKEN) Nagasaki University, Nagasaki, Japan hiraken@nagasaki-u.ac.jp Tel: Professor Dr. Kesara Na-Bangchang Director, Clinical Coordination and Training Center, Thammasat University Faculty of Allied Health Sciences, Thammasat University kesaratmu@yahoo.com Tel:
3 Venue: Seminar Room No. 125, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Sakamoto Campus) Registration deadline: 15 October, 2013 (We also accept onsite registration however registration kit materials are not guaranteed) Administration Office The information should be sent to Ms. Ikumi Frizt secretary, Diploma Course Office, Institute of Tropical Medicine, Nagasaki University
4 Module 1: Introduction Recognize the concept needs of PRD in medical and global view of health October 28, Monday (Day 1) 09:30-09:45 Welcome address Professor Dr. Kenji Hirayama, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan 09:45-10:00 Objective of the course and expectation, Pre-test 10:00-10:15 Break Professor Dr. Kenji Hirayama, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan 10:15-11:15 Overview of product research and development and stakeholders Professor Dr. Juntra Karbwang-Laothavorn, Nagasaki University, Japan 11:15-12:15 Key medical and public health issues, and the need for new products 12:15-14:00 Lunch Professor Dr. Kenji Hirayama, Institute of Tropical Medicine (NEKKEN) Nagasaki University, Japan Module 2: Drug Discovery and Development Session 1: Discovery Phase Describe the pharmacological process for drug discovery. Identify the process to protect intellectual property. 14:00-14:30 History and overview of drug discovery process Dr. Nobuhiro Noro, GlaxoSmith Kline, K.K., Japan 14:30-15:00 The role of Genomics and bioinformatics Dr. Nobuhiro Noro, GlaxoSmith Kline, K.K., Japan 15:00-15:30 High throughput screening: Pre-requisite of HITS systems, Assay Development & Validation, Biochemical & Cell-based assay, Assay Readout & Detection Dr. Nobuhiro Noro, GlaxoSmith Kline, K.K., Japan 15:30-15:45 Break 15:45-16:15 The role of Chemistry in Drug Discovery:-Lead Identification,
5 -Lead Generation Libraries (Combinatiorial Chemistry, Computational Approches), -Lead Optimization Dr. Nobuhiro Noro, GlaxoSmith Kline, K.K., Japan 16:15-16:45 Pharmacokinetic Issues in Drug Discovery: - Designs and Purposes of DMPK Profiles of Lead & Drug Candidates - DMPK studies in Drug Discovery (Late lead identification & Early lead optimization, Mid lead optimization, Late lead optimization) - Prediction of DMPK and PKPD Correlation - Prediction of Toxicity Dr. Nobuhiro Noro, GlaxoSmith Kline, K.K., Japan Session 2: Pre-clinical Development Describe the process of pharmacological development 16:45-17:45 Pharmaceutical Development and CMC Professor Dr. Hitoshi Sasaki, Nagasaki University Hospital, Japan October 29, Tuesday (Day 2) 09:00-09:45 The role of Pharmacology - Pharmacological Evaluations (Selectivity screening, Pharmacological profiling, Testing in animal models of disease, Safety pharmacology) - Examples 09:45-10:15 Biopharmaceuticals Professor Dr. Yoshimasa Tanaka, Nagasaki University, Japan - Development of Biopharmaceuticals - Type of Biopharmaceuticals - Issues Related to the use of Biopharmaceuticals (Antigenicity, Stability, Drug delivery) 10:15-10:30 Break 10:30-11:30 Drug Discovery in Academia
6 11:30-12:30 Patents in Drug Discovery: - Publication VS Patents - Patent system - Type of Patent Professor Dr. Hiroshi Kato, Nihon University, Japan 12:30-13:30 Lunch Session 2: Pre-clinical Development Describe the process of pharmacological development 13:30-14:00 Overview: Pre-clinical study requiments for human clinical studies 14:00-15:00 Assessing of Drug Safety: the role of toxicology - Objective and Type of Toxicology - Exploratory Toxicology - Regulatory Toxicology - Toxicity Measures and Toxicity Test Professor Dr. Kesara Na-Bangchang, Thammasat University, 15:00-15:15 Break 15:15-16:15 Pharmacokinetics October 30, Wednesday (Day 3) Session 3: Clinical Development 09:00-09:30 Overview of clinical development
7 Professor Dr. Juntra Karbwang-Laothavorn, Nagasaki University, Japan 09:30-11:00 Investigational Phases of Clinical Research (I-IV) and Study Design Professor Dr. Juntra Karbwang-Laothavorn, Nagasaki University, Japan 11:00-11:15 Break 11:15-12:15 Regulatory Framework Dr. Shimokawa Masafumi, Coordination Division Office of Planning and Coordination Pharmaceuticals and Medical Devi ces Agency 12:15-13:30 Lunch 13:30-14:00 Clinical Development Plan Professor Dr. Juntra Karbwang-Laothavorn, Nagasaki University, Japan 14:00-14:30 Pharmacogenomics - Anticipated Benefits - Polymorphisms in Drug Targets - Polymorphisms in ADME - Pharmacogenomics Testing - Pharmacogenomics in Clinical Trials - Examples Dr.Shyh-Yuh Liou, Takeda Pharmaceutical Company Limited Head Office, Japan 14:30-15:00 Pharmacokinetics in Clinical Development Extrapolation from animal to human pharmacokinetics Dr.Shyh-Yuh Liou, Takeda Pharmaceutical Company Limited Head Office, Japan 15:00-15:15 Break Session 4: Traditional Medicine Underline the importance of traditional medicine in PRD
8 15:15-16:10 Introduction of Traditional Medicine and Guidance on herbal medicine Professor Dr. Kiichiro Tsutani, The University of Tokyo, Japan 16:10-17:00 Regulation for traditional medicine development Dr. Ichiro Arai, Tsumura & Co., Japan 17:00-17:45 Rev and Exam 1 (Module 2) Professor Dr. Hirayama or Professor Dr. Kesara October 31, Thursday (Day 4) 10:00-17:00 Field Trip to Hisamitsu Pharmaceutical Co.,Inc Mr. Hiroyuki Hidaka, Hisamitsu Pharmaceutical Co.,Inc Module 3: Vaccine Development November 1, Friday (Day 5) Session 1: Discovery Describe the principles of basic immunology. Describe the process of vaccine discovery 09:00-09:30 Historical overview of vaccine Discovery Professor Dr. Kenji Hirayama, Nagasaki University, Japan 09:30-10:30 Vaccines for infection control Professor Dr. Kenji Hirayama, Nagasaki University, Japan 10:30-10:45 Break 10:45-12:15 Vaccines for infection control Professor Dr. Kenji Hirayama, Nagasaki University, Japan 12:15-13:30 Lunch 13:30-14:30 Vaccine Platform Technology and Adjuvant Development Dr. Takeshi Arakawa, University of the Ryukyus, Japan Session 2: Pre-Clinical Development Describe the process of pre-clinical development of vaccine 14:30-15:00 CMC Dr. Takeshi Arakawa, University of the Ryukyus, Japan 15:00-15:15 Break 15:15-15:45 Immunogenicity and protect activity assessment
9 Dr. Takeshi Arakawa, University of the Ryukyus, Japan 15:45-16:30 Safety assessment:toxicity test in animals: regional complications, systemic toxicity Dr. Takeshi Arakawa, University of the Ryukyus, Japan November 4, Monday (Day 6) Session 3: Clinical Development Describe the process of vaccine clinical development 09:00-10:00 Assessment of pre-clinical information TBD 10:00-10:30 Clinical development plan TBD 10:30-10:45 Break 10:45-11:45 Dose selection and regimen TBD 11:45-13:30 Lunch 13:30-15:45 Case studies Professor Dr. Kenji Hirayama, Nagasaki University, Japan 15:45-16:00 Break 16:00-17:00 Rev and Exam 3 (Module 3) Professor Dr. Kenji Hirayama, Nagasaki University, Japan Module 4: Diagnostic Development November 5, Tuesday (Day 7) Describe the process of discovery and development of diagnostic tools 09:00-10:00 Discovery and development of diagnostic tools Dr. Masato Sasaki, QIAGEN, Japan 10:00-10:30 Prototype production and assessment Dr. Masato Sasaki, QIAGEN, Japan
10 10:30-10:45 Break 10:45-11:45 Scale-up, manufacture and control Dr. Masato Sasaki, QIAGEN, Japan 11:45-12:30 Development of kits Dr. Masato Sasaki, QIAGEN, Japan 12:30-13:45 Lunch 13:45-14:45 Quality assurance/quality control: evaluation of efficacy after application Dr. Masato Sasaki, QIAGEN, Japan 14:45-15:45 Clinical development: validate prototype, manufacture pilot lot, initiate clinical trial Dr. Masato Sasaki, QIAGEN, Japan 15:45-16:00 Break 16:00-16:30 Clinical development: Supply chain logistics and production, Statistical Dr. Masato Sasaki, QIAGEN, Japan 16:30-17:00 Rev and Exam 4 (Module 4) Professor Dr. Kenji Hirayama and Professor Dr.Kesara Na- Bangchang Professor Dr. Kenji Hirayama, Nagasaki University, Japan Module 5: Good Clinical Practice November 6, Wednesday (Day 8) Describe the concepts of GCP, Recognise the principles of Ethics in research and the functions of Ethics Committee 09:00-09:30 Concept of Good Clinical Practice Professor Dr. Juntra Karbwang, Nagasaki University, Japan 09:30-10:30 Principles of Research Ethics and Ethics codes and Guidance Professor Dr. Juntra Karbwang, Nagasaki University, Japan 10:30-10:45 Break
11 10:45-11:45 Responsibilities: Sponsor, Monitors, audit, DSMB Professor Dr. Juntra Karbwang, Nagasaki University, Japan 11:45-12:30 Responsibilities of EC Professor Dr. Juntra Karbwang, Nagasaki University, Japan 12:30-13:30 Lunch 13:30-16:00 Case studies Professor Dr. Juntra Karbwang, Nagasaki University, Japan 16:00-16:30 Break 16:30-17:00 Review and Exam Professor Dr. Juntra Karbwang, Nagasaki University, Japan Module 6: Clinical Data Management November 7, Thursday (Day 9) Describe clinical data management processes, Describe how to write a good SOP for CDM 09:00-10:00 Overview, Protocol, CRF, SOPs Professor Dr. Kesara Na-Bangchang, Thammasat University 10:00-11:00 Data management process I 11:00-11:15 Break 11:15-11:45 Data management process I (Demo) 11:45-12:15 Data management process II 12:15-13:15 Lunch 13:15-13:45 Data management II (Demo) Ms. Panida Kongjam, Thammasat University Clinical Data
12 Management Center, 13:45-14:15 Data management process III 14:15-15:15 Data management process III (Practice) Ms. Panida Kongjam, Thammasat University Clinical Data Management Center, 15:15-16:15 Statistical analysis and sample size estimation 16:15-16:45 Rev and Exam 6 (Module 6) Module 7: Post-registration Activities November 8, Friday (Day 10) Describe post-registration activities for medicinal products 09:00-10:00 Overview Professor Chitr Sitthi-amorn, Chulalongkorn University, Bangkok, 10:00-11:00 How to solve Access to Medicines (ATM) problems in developing countries Professor Chitr Sitthi-amorn, Chulalongkorn University, Bangkok, 11:00-11:15 Break
13 11:15-12:15 Improving the quality of new products in health systems: International network of rational use of drugs Professor Chitr Sitthi-amorn, Chulalongkorn University, Bangkok, 12:15-13:15 Lunch 13:15-14:15 Post-marketing product vigilance Professor Chitr Sitthi-amorn, Chulalongkorn University, Bangkok, 14:15-15:15 Stakeholders to be involved in making product development work for the intended beneficiaries Professor Chitr Sitthi-amorn, Chulalongkorn University, Bangkok, 15:15-15:30 Break 15:30-16:30 Intellectual Property Rights Protection in Developing Countries Professor Hiroko Yamane, Teikyo University, Japan 16:30-17:00 Rev and Exam 2 (Module 7) Professor Dr. Kenji Hirayama, Nagasaki University, Japan November 9, Saturday (Day 11) 9:00-11:00 FINAL EVALUATION. COURSE ASSESSMENT Professor Dr. Kenji Hirayama, Nagasaki University, Japan Professor Dr. Juntra Karbwang, Nagasaki University, Japan, Course Director 11:00-12:00 CLOSING CEREMONY Professor Dr. Kenji Hirayama, Institute of Tropical Medicine (NEKKEN) Nagasaki University, Japan
14
15
16
17
18
Diploma Course on Research & Development of Products to Meet Public Health Needs
Diploma Course on Research & Development of Products to Meet Public Health Needs Organized by Institute of Tropical Medicine (NEKKEN), Center for International Collaborative Research (CICORN), Nagasaki
Masters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
Roles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
Sheffield Kidney Institute. Planning a Clinical Trial
Planning a Clinical Trial Clinical Trials Testing a new drug Ethical Issues Liability and Indemnity Trial Design Trial Protocol Statistical analysis Clinical Trials Phase I: Phase II: Phase III: Phase
Pharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
DMPK: Experimentation & Data
DMPK: Experimentation & Data Interpretation Mingshe Zhu, Mike S. Lee, Naidong Weng, and Mark Hayward Prerequisite: Entry-level scientists with hands on experience in LC/MS as well as advanced students
A clinical research organization
A clinical research organization About Us State of art facility. All clinical trials carried out in accordance with ICH GCP guidelines. Quality services within stipulated time period. Team of experienced
The Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
MSc in Toxicology. Master Degree Programme
Master Degree Programme MSc in Toxicology Department of Pharmaceutical Sciences, University of Basel Swiss Centre for Applied Human Toxicology (SCAHT) Master of Science in Toxicology University of Basel
GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
Overview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
SYLLABUS. Drug development in a New Era: NYU GSAS, MSc, Sackler, SOM 2012
Drug development in a New Era: NYU GSAS, MSc, Sackler, SOM 2012 Course Description: Bringing a new chemical entity, drug, or device to the consumer market is a necessary but intricate, expensive, complicated,
Programme Guide PGDCDM
Post Graduate Diploma in Clinical Data Management and Biostatistics with SAS Programme Guide PGDCDM School of Health Sciences Indira Gandhi National Open University WHY THIS PROGRAMME? The Post Graduate
Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials
Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Ron Hinkel, Director Quality Systems BioReliance Inc. Patti Rossman, President Globiox Purpose Keep pace
CLINICAL PHARMACOLOGY
0 :: 2 v01 x y p.345 B xxx.:: B A x y pval«««[xy] -løøøø xxx.:: øøøø -0.02-0.01-0.00 0.00 0.01 0.02.1.2 A PHARMATRAIN CENTRE OF EXCELLENCE EXPLORATORY & CONFIRMATORY CLINICAL DEVELOPMENT: CLINICAL PHARMACOLOGY
de formation continue Diploma of Advanced Studies Management of Clinical Trials Good Clinical Practice Implementation and Quality Processes
DAS Diplôme de formation continue Diploma of Advanced Studies Management of Clinical Trials Good Clinical Practice Implementation and Quality Processes October 2015 September 2016 CRC Centre de Recherche
Drug Safety of Stem Cells and other Novel Therapeutics
Course 1.2 Drug Safety of Stem Cells and other Novel Therapeutics 13 17 October 2014 MRC Centre for Drug Safety Science Institute of Translational Medicine University of Liverpool, Liverpool, UK European
S P E C I A L I S T A N D M A S T E R S T U D I E S
University Ss, Cyril and Methodius Skopje FACULTY OF PHARMACY S P E C I A L I S T A N D M A S T E R S T U D I E S Healthcare management and pharmacoeconomics Skopje, 2007 STUDY PLAN -Specialist Studies-
Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
THE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science
CURRICULUM FOR RESEARCH POSTGRADUATE PROGRAMS Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science Curriculum for Master of Philosophy (MPhil) Program in Life Science The
4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
PharmD Postdoctoral Fellowship Program
Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the
Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
History and Principles of Good Clinical Practice
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
Master of Science in Biomedical Sciences
Master of Science in Biomedical Sciences Faculty of Medicine Good health is our greatest treasure. Understanding the human body, healthy and diseased, is the stepping stone to finding tools to improving
TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
exactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
Oversight of Clinical Trials in Europe - Member State perspective. Gunnar Danielsson Senior Expert Pharmaceutical Inspector
Oversight of Clinical Trials in Europe - Member State perspective Gunnar Danielsson Senior Expert Pharmaceutical Inspector Oversight of Clinical Trials Oversight of clinical trials occur on many different
Organization Profile. IT Services
Introduction In today s scientific and medical world, various issues in clinical trials and research have permeated every society and every field in medicine. Ethics and in particular the quality of research
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS,
Kazan (Volga region) Federal University, Kazan, Russia Institute of Fundamental Medicine and Biology. Master s program.
Kazan (Volga region) Federal University, Kazan, Russia Institute of Fundamental Medicine and Biology Master s program Bioinformatics I. THEORETICAL BASIS The development of effective technologies of theoretical
Master of Science in Medical Writing Curriculum*
University Program Master of Science in Medical Writing Curriculum* Medical University of Innsbruck *This is a translation of the original, German document found here: https://www.imed.ac.at/mitteilungsblatt/2012/58.pdf
Careers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA
PharmaSUG 2014 Paper CP07 Careers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA ABSTRACT In the biopharmaceutical
Promoting innovation and improving access
NATIONAL ASSESSMENT TOOL TO ASSIST MEMBER STATES IN IMPLEMENTING THE GLOBAL STRATEGY AND PLAN OF ACTION ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY Promoting innovation and improving access
The AVAREF joint review process of Ebola clinical trial applications
The AVAREF joint review process of Ebola clinical trial applications Dr Matthias Stahl, Regulation, Ebola R&D Team 1 Background WHO convened the 9 th annual meeting of the African Vaccine Regulatory Forum
1. Program Title Master of Science Program in Biochemistry (International Program)
1 Program Structure and Specification Master of Science Program in Biochemistry (International Program) Curriculum Last Revised in 2012 for Students Entering in Academic Year 2016 -----------------------------------------
PharmaPendium. The definitive source of best-in-class drug information
Please contact us for more information Americas E-Customer Service 360 Park Avenue South New York, NY 10010-1710 USA Tel: +1 888 615 4500 (+1 212 462 1978, if calling from outside the USA and Canada) Fax:
Programme Specification
Programme Specification Awarding Body/Institution Teaching Institution Queen Mary, University of London Queen Mary, University of London Name of Final Award and Programme Title MSc, PG Dip or PG Cert in
From Drug Discovery to First in Humans
0 :: 2 v01 x y p.345 B xxx.:: B A x y pval«««[xy] -løøøø xxx.:: øøøø -0.02-0.01-0.00 0.00 0.01 0.02.1.2 A PharmaTrain Centre of Excellence Non-Clinical Testing, Pharmaceutical & Early Clinical Development:
The majority of pharmaceutical companies in
Pharmaceutical Infrastructure and Industry Professor Che-Ming Teng, Ph.D. National Taiwan University College of Medicine, Taipei, Taiwan The majority of pharmaceutical companies in Taiwan are devoted to
Workshop on Capacity Building of Ethics Committees for Clinical Research in India 08 April 2015, PIMS, Puducherry
Objective: To strengthen the knowledge about the requirements for ethical conduct, review of study documents, statistical fundamentals, and reporting and analysis of serious adverse events during clinical
TEMPLATE DATA MANAGEMENT PLAN
TEMPLATE DATA MANAGEMENT PLAN ICRIN (QM sub group) Version: XX Date: XXXXXXX Page 1 of 6 1.0 Document Ownership The Data Management Plan (DMP) will be initiated and subsequently owned by the Data Manager
Future Specialisation for Pharmacists in Industry
Future Specialisation for Pharmacists in Industry JANE NICHOLSON Executive Director European Industrial Pharmacists Group (EIPG) Innovation gap... Cost is now ~ 700-1billion Success Rate 1 in 10,000 By
Importing pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
Introduction to pharmaceutical technology
Introduction to pharmaceutical technology Marie Wahlgren Chapter 1 What is the topics of today Introduction to the course Introduction to the project assignment How to choose a new drug formulation 1 Contacts
Conditions for Accreditation as (Basic) Pharmacologist
NEDERLANDSE VERENIGING VOOR FARMACOLOGIE DUTCH PHARMACOLOGICAL SOCIETY Conditions for Accreditation as (Basic) Pharmacologist 1. Introduction The Dutch Pharmacological Society (DPS) is the organization
Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure
Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National
School of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034. Phone: 267.468.8560 Fax: 267.468.
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034 Phone: 267.468.8560 Fax: 267.468.8565 POST-MASTER S CERTIFICATE in CLINICAL TRIAL MANAGMENT Designed for Pharmaceutical
Master of Science in Vision Science and Investigative Ophthalmology MVSIO
Master of Science in Vision Science and Investigative Ophthalmology MVSIO Global Leadership in Eye Care, Vision Research and Ophthalmology Education Bascom Palmer Eye Institute is pleased to introduce
A responsible approach to clinical trials. Bioethics in action
A responsible approach to clinical trials Bioethics in action What is bioethics? At Novo Nordisk bioethics is the expression used for all ethical issues related to the use of life science technologies
Certified National Pharmaceutical Representative
Certified National Pharmaceutical Representative 120 hours Course Overview/Description The Certified National Pharmaceutical Representative (CNPR) online training program was developed in partnership with
Revised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14)
Revised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14) Documents to be submitted for grant of permission to conduct BA/BE studies in Human Subjects/Patients
PHARMACEUTICAL INDUSTRY Fellowship Program
PHARMACEUTICAL INDUSTRY Fellowship Program USC School of Pharmacy 2015-2016 In partnership with ABOUT OUR COMPANY Allergan, headquartered in Dublin, Ireland, is a unique, global pharmaceutical company
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL
Guidance for Industry
Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance
PROGRAM DESCRIPTION ADMISSION STANDARDS
PROGRAM DESCRIPTION The goal of the graduate program in Pharmaceutical Sciences at Texas Southern University College of Pharmacy and Health Sciences is to offer broad-based education to prepare independent
Master Program in Vaccinology and Pharmaceutical Clinical Development
III Edition May 2013 - November 2014 Siena, Italy Master Program in Vaccinology and Pharmaceutical Clinical Development University of Siena Medical School Index Sponsors 3 Technical-Scientific Committee
Operational aspects of a clinical trial
Operational aspects of a clinical trial Carlo Tomino Pharm.D. Coordinator Pre-authorization Department Head of Research and Clinical Trial Italian Medicines Agency Mwanza (Tanzania), June 11, 2012 1 Declaration
Pediatric Trials Network. Danny Benjamin MD PhD Professor of Pediatrics Duke University www.dcri.org/about-us/conflict-of-interest
Pediatric Trials Network Danny Benjamin MD PhD Professor of Pediatrics Duke University www.dcri.org/about-us/conflict-of-interest Pediatric Drug Development 1998: essentially no trials Mandate (Pediatric
Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
Monday 18 April Registration of participants and distribution of material Introduction to International Criminal Law (ICL) Coffee Break
University of Turin Department of Law Seminar on International Criminal Law Defence 18 22 April 2016 Application deadline: 3 April 2016 in cooperation with the Office of Public Counsel for the Defence
MASTERS PROGRAMME IN VACCINOLOGY AND PHARMACEUTICAL CLINICAL DEVELOPMENT
Siena, Italy June 2011 December 2012 MASTERS PROGRAMME IN VACCINOLOGY Programme Organized by: University of Siena, Medical School Novartis Vaccines Novartis Vaccines Institute for Global Health Siena -
ENTRY-LEVEL DOCTOR OF ACUPUNCTURE AND ORIENTAL MEDICINE (DAOM EL) PROGRAM FOR PCOM ALUMNI
ENTRY-LEVEL DOCTOR OF ACUPUNCTURE AND ORIENTAL MEDICINE (DAOM EL) PROGRAM FOR PCOM ALUMNI The Entry-Level Doctor of Acupuncture and Oriental Medicine (DAOM EL)* is designed to accomplish the following
ICH Topic E 8 General Considerations for Clinical Trials. Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95)
European Medicines Agency March 1998 CPMP/ICH/291/95 ICH Topic E 8 General Considerations for Clinical Trials Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95) TRANSMISSION
PG Certificate / PG Diploma / MSc in Clinical Pharmacy
PG Certificate / PG Diploma / MSc in Clinical Pharmacy Programme Information September 2014 Entry School of Pharmacy Queen s University Belfast Queen s University Belfast - Clinical Pharmacy programme
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
Challenges in the Regulation of Pediatric Clinical Trials
Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting
BS in Pharmaceutical Science (BSPS) degree program University of Rhode Island
To prepare students for careers in the pharmaceutical, biotechnical, consumer product and health care industries. Types of work include laboratory, regulatory oversight, engineering, economics, marketing,
M110.726 The Nucleus M110.727 The Cytoskeleton M340.703 Cell Structure and Dynamics
of Biochemistry and Molecular Biology 1. Master the knowledge base of current biochemistry, molecular biology, and cellular physiology Describe current knowledge in metabolic transformations conducted
Overview of CDISC Implementation at PMDA. Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA)
Overview of CDISC Implementation at PMDA Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA) CDISC 2012 Outline Introduction Update of PMDA activity CDISC implementation
NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1
NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1 2 The National Agency of Drug and Food Control (NA-DFC) is a non departmental
2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life
Clinical Trials: The Crux of Cancer Innovation
Clinical Trials: The Crux of Cancer Innovation Even as medical science is transforming cancer care, major deficiencies in the way cancer clinical trials are designed, carried out, regulated and funded
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY
MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY Academic Reference Standards of Pharm.-D Program College of Pharmacy-University of Hail May The Major shift in the health-care system
Even we will get to use your product someday. Enough reason for us to deliver.
Even we will get to use your product someday. Enough reason for us to deliver. ClinInvent: Putting our heart and soul behind the research. At ClinInvent, when we talk about clinical research it s not just
Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit?
ELLEN PURÉ, Ph.D. Issues Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? Can the academic review process support individual career development in
Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements
Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Pharmaceutical Sciences Applied sciences that underlie the practice of pharmacy the development, manufacture,
General Response Rates
General Response Rates 42 Responses 28 Programs stated that they had a PharmD/PhD program and typically responded to questions about PharmD/PhD Training 16 Programs stated that they had a Clinical Pharmaceutical
POST-MASTER S CERTIFICATES in ADVANCED QUALITY ASSURANCE or REGULATORY AFFAIRS
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034 Phone: 267.468.8560 Fax: 267.468.8565 POST-MASTER S CERTIFICATES in ADVANCED QUALITY ASSURANCE or REGULATORY
Clinical Trial Trends Outline Complexity for Supply Chain. Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.
Clinical Trial Trends Outline Complexity for Supply Chain Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.com 29 May 2013 Biotechnology Sales on the Rise Source: EvaluatePharma
Pharmaceutical Sciences
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aapspharmaceutica.com/students How do I know if a career in the pharmaceutical sciences
FY2016 Application guideline for Graduation Program for Leaders in Life Innovation
FY2016 Application guideline for Graduation Program for Leaders in Life Innovation Program outline In the world of low birthrate and longevity, life innovation in both basic and application that helps
MUNI UNIVERSITY EMPLOYMENT OPPORTUNITY. (External Advert No.3 2015)
MUNI UNIVERSITY MUNI UNIVERSITY Office of the University Secretary P.O. Box 725 Arua, Uganda Tel: +256 476 420312/3/4; Fax: +256 476 420316 Email: info@muni.ac.ug/inquiries@muni.ac.ug www.muni.ac.ug EMPLOYMENT
Data Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International
Data Management and Good Clinical Practice Patrick Murphy,, Family Health International 1 What is GCP? Good Clinical Practice is an international ethical and scientific quality standard for designing,
MCPHS University and Pfizer. Biopharmaceutical Industry Fellowship Program
MCPHS University and Pfizer Biopharmaceutical Industry Fellowship Program Fast Facts Location : Groton, Connecticut Fellowship Programs Global Clinical Supply : Quality Assurance Length : Two years Requirements
Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right
1 www.imarcresearch.com
Risk Management in Clinical Research: PROCESS DEVELOPMENT & APPLICATION Introduction Recently, two key pieces of guidance were released from Food and Drug Administration (FDA) and European Medicines Agency
Effective project planning and evaluation in biomedical research
TRAINERS Effective project planning and evaluation in biomedical research TRAINING MANUAL Special Programme for Research & Training in Tropical Diseases (TDR) sponsored by UNICEF/UNDP/World Bank/WHO TDR/RCS/PPE/T/07.1
Exploiting the Pathogen box
Exploiting the Pathogen box Dr Richard Gordon Director Strategic Health Innovation Partnerships 9 May 2014 www.ship.mrc.ac.za Background Worked with MMV in many areas Servicing Partner Consultant Collaborator
A Core Clinical Research Hospital to provide world class advanced medical care
Basic Principals 1 2 3 Providing safe and highquality medical care as a patient-centered hospital Contributing to society through the development and practice of new treatments Fostering medical professionals
Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia
Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity
Short Course on Fundamentals of Clinical Data Management (CDM)
Short Course on Fundamentals of Clinical Data Management (CDM) Course offered by Advanced Clinical Data Management Centre (ACDMC), Biostatistics Resource and Training Centre, Department of Biostatistics,
The MSCR Curriculum and Its Advantages
Masters of Science in Clinical Research (MSCR) Curriculum Goal/Objective of the MSCR The MSCR program is an interdisciplinary research degree program housed within the Department of Epidemiology in the